206 related articles for article (PubMed ID: 10760284)
1. High metastatic potential in mice inheriting a targeted p53 missense mutation.
Liu G; McDonnell TJ; Montes de Oca Luna R; Kapoor M; Mims B; El-Naggar AK; Lozano G
Proc Natl Acad Sci U S A; 2000 Apr; 97(8):4174-9. PubMed ID: 10760284
[TBL] [Abstract][Full Text] [Related]
2. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.
Alexandrova EM; Mirza SA; Xu S; Schulz-Heddergott R; Marchenko ND; Moll UM
Cell Death Dis; 2017 Mar; 8(3):e2661. PubMed ID: 28277540
[TBL] [Abstract][Full Text] [Related]
3. Frequent retention of heterozygosity for point mutations in p53 and Ikaros in N-ethyl-N-nitrosourea-induced mouse thymic lymphomas.
Kakinuma S; Nishimura M; Kubo A; Nagai JY; Amasaki Y; Majima HJ; Sado T; Shimada Y
Mutat Res; 2005 May; 572(1-2):132-41. PubMed ID: 15790496
[TBL] [Abstract][Full Text] [Related]
4. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.
Venkatachalam S; Shi YP; Jones SN; Vogel H; Bradley A; Pinkel D; Donehower LA
EMBO J; 1998 Aug; 17(16):4657-67. PubMed ID: 9707425
[TBL] [Abstract][Full Text] [Related]
5. Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells.
Pollock RE; Lang A; Luo J; El-Naggar AK; Yu D
Oncogene; 1996 May; 12(9):2035-9. PubMed ID: 8649865
[TBL] [Abstract][Full Text] [Related]
6. Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors.
Shetzer Y; Napchan Y; Kaufman T; Molchadsky A; Tal P; Goldfinger N; Rotter V
Int J Cancer; 2017 Mar; 140(6):1364-1369. PubMed ID: 28008605
[TBL] [Abstract][Full Text] [Related]
7. Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene.
Kikuchi-Yanoshita R; Tanaka K; Muraoka M; Konishi M; Kawashima I; Takamoto S; Hirai H; Miyaki M
Oncogene; 1995 Oct; 11(7):1339-45. PubMed ID: 7478555
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity in p53 mutations in mouse mammary tumor subpopulations with different metastatic potential from the orthotopic site.
Shekhar PV; Werdell J; Christman JK; Miller FR
Anticancer Res; 1995; 15(3):815-20. PubMed ID: 7645964
[TBL] [Abstract][Full Text] [Related]
9. P53 levels determine outcome during beta-catenin tumor initiation and metastasis in the mammary gland and male germ cells.
Ridgeway AG; McMenamin J; Leder P
Oncogene; 2006 Jun; 25(25):3518-27. PubMed ID: 16434961
[TBL] [Abstract][Full Text] [Related]
10. Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer.
Thompson TC; Park SH; Timme TL; Ren C; Eastham JA; Donehower LA; Bradley A; Kadmon D; Yang G
Oncogene; 1995 Mar; 10(5):869-79. PubMed ID: 7534899
[TBL] [Abstract][Full Text] [Related]
11. Tumor spectrum analysis in p53-mutant mice.
Jacks T; Remington L; Williams BO; Schmitt EM; Halachmi S; Bronson RT; Weinberg RA
Curr Biol; 1994 Jan; 4(1):1-7. PubMed ID: 7922305
[TBL] [Abstract][Full Text] [Related]
12. Malignant transformation of human fibroblast cell strain MSU-1.1 by N-methyl-N-nitrosourea: evidence of elimination of p53 by homologous recombination.
Boley SE; McManus TP; Maher VM; McCormick JJ
Cancer Res; 2000 Aug; 60(15):4105-11. PubMed ID: 10945617
[TBL] [Abstract][Full Text] [Related]
13. Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss.
Blyth K; Terry A; O'Hara M; Baxter EW; Campbell M; Stewart M; Donehower LA; Onions DE; Neil JC; Cameron ER
Oncogene; 1995 May; 10(9):1717-23. PubMed ID: 7753548
[TBL] [Abstract][Full Text] [Related]
14. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice.
Harvey M; Vogel H; Morris D; Bradley A; Bernstein A; Donehower LA
Nat Genet; 1995 Mar; 9(3):305-11. PubMed ID: 7773294
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis.
Heinlein C; Krepulat F; Löhler J; Speidel D; Deppert W; Tolstonog GV
Int J Cancer; 2008 Apr; 122(8):1701-9. PubMed ID: 18092324
[TBL] [Abstract][Full Text] [Related]
16. Hprt mutant frequency and p53 gene status in mice chronically exposed by inhalation to benzene.
Albertini RJ; Judice SA; Recio L; Walker VE
Chem Biol Interact; 2010 Mar; 184(1-2):77-85. PubMed ID: 20035728
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic pathway of sporadic colorectal cancer with novel germline missense mutations in the hMSH2 gene.
Yamada K; Zhong X; Kanazawa S; Koike J; Tsujita K; Hemmi H
Oncol Rep; 2003; 10(4):859-66. PubMed ID: 12792735
[TBL] [Abstract][Full Text] [Related]
18. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract.
Furihata M; Takeuchi T; Matsumoto M; Kurabayashi A; Ohtsuki Y; Terao N; Kuwahara M; Shuin T
Clin Cancer Res; 2002 May; 8(5):1192-5. PubMed ID: 12006537
[TBL] [Abstract][Full Text] [Related]
19. Cis lethal genetic interactions attenuate and alter p53 tumorigenesis.
Wang Y; Zhang W; Edelmann L; Kolodner RD; Kucherlapati R; Edelmann W
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5511-5. PubMed ID: 20212136
[TBL] [Abstract][Full Text] [Related]
20. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas.
Komuro H; Hayashi Y; Kawamura M; Hayashi K; Kaneko Y; Kamoshita S; Hanada R; Yamamoto K; Hongo T; Yamada M
Cancer Res; 1993 Nov; 53(21):5284-8. PubMed ID: 8221663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
